HEALTH

LANGHORNE, Pa. — Insight Pharmaceuticals has launched a mobile application for its E.P.T. brand.

The new E.P.T. ovulation calculator features an easy-to-use interface that's designed to help users who are trying to get pregnant know when they are most fertile, or simply keep track of their menstrual cycle, the company said. The app — which currently is available for the iPhone, iPad, and iPod Touch, and supports Apple iOS 5 — also comes with 35 fertility tips and is equipped to provide email or calendar reminders on the day before expected ovulation.

IRVINGTON, N.Y. — Genomma Lab is planning to present a list of candidates to serve on the board of directors of Prestige Brands.

The announcement followed Genomma Lab's unsolicited proposal to acquire Prestige Brands for $16.60 per share in cash. Although the deal was rejected, Genomma Lab intends to present the list at Prestige Brands' upcoming annual meeting in June.

NEW YORK — Reducing the cutoff of hemoglobin A1C to determine if a patient has prediabetes could be cost effective, according to a new study.

NEW YORK — A bacterium found in the stomach may be associated with diabetes, according to a study published in the Journal of Infectious Diseases.

NEW YORK — Women that are seated for longer periods of time are more likely to develop diabetes when compared with men, according to a new study.

WASHINGTON — West Virginia has become the 19th state to require pharmacists and other retailers to be connected through the National Precursor Log Exchange system with the passage of legislation that requires real-time, stop-sale technology to enable the state's pharmacists to block illegal pseudoephedrine purchases right at the point of sale and provide law enforcement with up-to-the minute criminal data.

NEW YORK — Pfizer and Indian drug maker Biocon have ended a partnership that the companies started in 2010 to develop biosimilar treatments for diabetes, the companies said.

IRVINGTON, N.Y. — Prestige Brands has rejected an unsolicited proposal from Genomma Lab, which seeks to acquire the over-the-counter and household cleaning products maker for $16.60 per share in cash, calling the deal inadequate, opportunistic and highly conditional.